erlotinib + chemotherapy

Erlotinib is a small molecule tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR). It works by reversibly binding to the ATP-binding site of EGFR, thereby inhibiting its kinase activity and blocking downstream signaling pathways involved in cell proliferation and survival. Erlotinib is primarily indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) with specific EGFR mutations (exon 19 deletions or exon 21 L858R substitution mutations), as well as for advanced pancreatic cancer in combination with gemcitabine. When used with chemotherapy, erlotinib is specifically approved in combination with gemcitabine for pancreatic cancer; it is not recommended for use alongside platinum-based chemotherapies[1][3][5][7].

Brand names

Tarceva

Other names

erlotinib plus chemotherapyerlotinib beyond progressionerlotinib and chemotherapy